Clinical Trials Directory

Clinical Trials Directory

Are you interested in taking part in a clinical trial? Our Clinical Trials Directory includes all active clinical trials at The University of Tennessee Medical Center.

Moving Medical Knowledge Forward, Every Day

Doctors and researchers at The University of Tennessee Medical Center work together diligently. Our goal is to discover new and better ways to find and treat disease. We do this through various research projects and clinical trials.

Research projects at the medical center help move forward medical knowledge. The National Institutes of Health and related agencies fund researchers on our campus to bring the best of medical care to East Tennessee. Plus, our physicians provide clinical trial opportunities for our patients. We make them readily available to those who seek new medications and treatment.

Our research teams work closely with researchers throughout the University of Tennessee system as well as others throughout the nation.

The University of Tennessee Medical Center brings together outstanding patient care, challenging clinical training and stimulating research – all on one campus.

Clinical Trials Directory

Cancer Institute

Acute Myeloid Leukemia

Celgene CONNECT – The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Dysfunctional CVADs

Chiesi Ready 1 CUSA-081-HEM-01 – A Phase 3, Randomized, Double-Blind, Active and Placebo-Controlled Study on the use of CUSA-081 for Dysfunctional Central Venous Access Devices (CVADs).

Endometrial Cancer

Tesaro RUBY 4010-03-001 – A Phase 3, randomized, double-blind, multicenter study to evaluate the efficacy and safety of TSR-042 plus carboplatin-paclitaxel versus placebo plus carboplatin-paclitaxel in patients with first line stage III/IV or recurrent endometrial cancer in all comers (allows USC and MMMT).

Follicular Lymphoma

Dr. Reddy’s RI-01-006 Follicular Lymphoma – Phase 3 trial to Compare the Efficacy and Safety of a DRL_RI with MabThera® in patients with previously untreated, Stage II-IV, CD20-positive, low tumor burden follicular lymphoma 1st Line. IP is a proposed biosimilar version of rituximab.


Astrazeneca EMERALD A Phase III, Randomized, Double-blind, Placebo-Controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination with either Durvalumab Monotherapy or Durvalumab plus Bevacizumab Therapy in Patients with Locoregional Hepatocellular Carcinoma.

Hodgkin’s Lymphoma

Seattle Genetics SGN35-027– A+AVD with G-CSF in Treatment-Naïve Hodgkin Lymphoma (SGN35-027).


Trillium TTI-622-01 – A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-622 in Patients with Advanced Relapsed or Refractory Lymphoma or Myeloma.


Amgen Herpetic Infection 20130193 – A post-marketing prospective cohort study of Melanoma patients treated with Imlygic (Talimogene Laherparepvec) in clinical practice to characterize the risk of Herpetic infection among patients, close contacts, and health care providers, and long-term safety in treated patients

Array 818-103 – Phase 1 study to evaluate the effects of Encorafenib in combination with Binimetinib on the pharmacokinetics of Losartan, Midazolam, Caffeine, Omeprazole, and Dextromethorphan administered in a cocktail approach and on the pharmacokinetics of Rosuvastatin in patients with BRAF V600-mutant unresectable or Metastatic BRAF V600-mutant Melanoma or other advanced solid tumors.

Merck MK-3475-716 – A randomized, double-blind phase 3 study of Adjuvant therapy with Pembrolizumab versus Placebo in Resected high risk stage II Melanoma.

Newlink Genetics NLG0304 – Phase 2B study of Ipilimumab with or without Hyperacute-Melanoma (HAM) Immunotherapy for patients with Stage 4 Melanoma.

Multi Cancers

Altor Biosciences Quilt 3.055 – A Phase 2b, single-arm, multicohort, open-label study of ALT-803 in combination with a PD-1/PD-L1 checkpoint inhibitor in patients who have disease progression following an initial response to treatment in PD-1/PD-L1 checkpoint inhibitor therapy.

Non Small Cell Lung Cancer

Altor Bioscience Quilt 2.023 – A study of ALT-803, a fusion protection activator of natural killer and T-cells, in combination with Pembrolizumab vs Pembrolizumab alone as first-line treatment for patients with metastatic non-small cell lung cancer.

AstraZeneca PACIFIC-5 – Phase 3, randomized, open-label, multi-center, international study in patients with locally advanced, unresectable NSCLC who have not progressed following definitive, platinum-based, concurrent chemo-radiation therapy

BrightPath GRN-1201 – A pilot, open-label, multi-center, multi-dose study of GRN-1201 added to Pembrolizumab in subjects with PD-L1+ Non-Small Cell Lung Cancer.

Merck MK-7339-006 – A phase 3 study of Pembrolizumab with maintenance Olaparib or maintenance Pemetrexed in first-line (1L) Metastatic nonsquamous non-small-cell lung cancer.

Oral Mucositis

Galera GTI-4419-301 – A phase 3, randomized, double-blind, placebo-controlled, multi-center study of the Superoxide dismutase mimetic GC4419 to reduce severe oral mucositis (SOM) associated with chemo radiotherapy for locally advanced, non-metastatic head and neck cancer.

Ovarian Cancer

Tesaro First – A Phase 3 comparison of platinum-based therapy with TSR-042 and Niraparib versus standard of care platinum -based therapy as first line treatment of Stage III or IV nonmucinous epithelial ovarian cancer.

Prostate Cancer

Lilly 13Y-MC-JPCM – A phase 2, randomized, double-blind, placebo-controlled study of Abiraterone Acetate plus Prednisone with or without Abemaciclib in patients with metastatic-castration-resistant prostate cancer.

Pancreatic Cancer

Astellas 1948-CL-0101 – A Phase 1b study of ASP1948, targeting an immune modulatory receptor, as a single agent and in combination with Nivolumab in subject with advanced solid tumors.

Urinary Cancer

No trials at this time.

Cutaneous Squamous Cell Carcinoma

Regeneron Case – A prospective survivorship cohort study of adult patients with cutaneous squamous cell carcinoma undergoing treatment with Cemiplimab.

Castle Biosciences CBI-2019-cSCC-PVS-001- Prospective Validation of a Gene Expression Assay to Predict the Risk of Recurrence Disease in Cutaneous Squamous Cell Carcinoma.

Multiple Myeloma

BMS/Parexel – PREAMBLE Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation

Urothelial Carcinoma

AstraZeneca PREVAIL – A Prospective, Non-Interventional Study to Assess PD-L1 Expression in the First-Line Setting of Locally Advanced/Unresectable or Metastatic Urothelial Carcinoma.

Brain and Spine


No trials at this time through The Office of Clinical Trials. Contact The Pat Summitt Clinic for information on trials originating there.


Penumbra SURF – Post-market, real world, prospective, multi-center study to demonstrate the safety and efficacy of the Penumbra SMART COIL System, including the WAVE extra soft coils as a fill and finish coil, in the treatment of intracranial aneurysms.

Vanderbilt/Stryker – Framing Eighteen coils in cerebral Aneurysms Trial (FEAT)

Cerenovus CNV-2017-01 – STERLING – A Prospective, Multi-Center, Single Arm Study to obtain “real world” clinical data and characterize the acute and long-term performance of the MICRUSFRAME and GALAXY coils for the endovascular treatment of intracranial aneurysms.

Ischemic Stroke

Cerenovus CNV-2017-02 – EXCELLENT post-marketing registry to collect and analyze stroke-inducing blood clots removed from the brain with its Embotrap II revascularization device.


Mayo STRIP – Stroke Thromboembolism Registry of Imaging and Pathology

Center for Women and Infants

Endometriosis Associated Pain

ObsEva/Covance OBE2109-002 – A Phase 3 multicenter, randomized, double-blind, placebo-controlled, clinical study to assess the efficacy and safety of study drug in subjects with moderate to severe endometriosis associated pain.

Heavy Menstrual Bleeding

Medicines 360 360-L105 – A Phase 3, multicenter, open-label study of a Levonorgestrel 52 mg intrauterine system for the treatment of heavy menstrual bleeding.

Premature Birth

MEDNAX OBX-0034 – Impact of a booster course of antenatal steroids on neonatal outcome in patients with premature rupture of the membranes.

Heart, Lung, Vascular Institute

End Stage Renal Disease

Humacyte CLN-PRO-V007 – A Phase 3 study to compare the efficacy and safety of Humacyte’s Human Acellular Vessel with that of an Autologous arteriovenous fistula in subjects with End-Stage Renal disease.

Cardiovascular Imaging Agent

GE-265-303 – A Phase 3, Open-label, study of Flupiridaz (18F) injection for Positron Emission Tomography (PET) imaging for assessment of myocardial perfusion in patients referred for invasive coronary angiography because of suspected coronary artery disease.

Cystic Fibrosis

Vertex/Covance VX17-659-105 – Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Who are Homozygous or Heterozygous for the F508del Mutation.

Vertex VX18-445-113 – VX18-445-113 Phase 3, Open-label Study Evaluating the Long-term Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis. Sites participating in 105 (above) automatically selected for 113.

Heart Failure

V-Wave -RELIEVE – Reducing lung congestion symptoms using the V-Wave shunt in advanced heart failure.

Primary Care and Other Studies

Thyroid Eye Disease

Horizon HZNP-TEP-401 – Phase 3b, multicenter, open-label, single arm expanded access protocol of TEPROTUMUMAB (HZN-001).

Contact Info
Office of Clinical Trials
1926 Alcoa Highway, Suite 344
Knoxville, TN 37920
865-305-4893 Find a Doctor Make an Appointment
Contact Info
Office of Clinical Trials
1926 Alcoa Highway, Suite 344
Knoxville, TN 37920
865-305-4893 Find a Doctor Make an Appointment

Start typing and press Enter to search